IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Up 4.1%

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report)'s share price rose 4.1% during mid-day trading on Tuesday . The company traded as high as $42.20 and last traded at $41.96. Approximately 754,542 shares changed hands during mid-day trading, a decline of 7% from the average daily volume of 809,608 shares. The stock had previously closed at $40.32.

Analyst Upgrades and Downgrades

IDYA has been the subject of a number of research reports. Wedbush reaffirmed an "outperform" rating and issued a $52.00 price objective on shares of IDEAYA Biosciences in a research note on Wednesday, May 8th. JPMorgan Chase & Co. upped their price objective on shares of IDEAYA Biosciences from $51.00 to $57.00 and gave the company an "overweight" rating in a research note on Friday, February 23rd. Capital One Financial reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a research note on Thursday, February 22nd. Leerink Partnrs reissued an "outperform" rating on shares of IDEAYA Biosciences in a research report on Friday, February 23rd. Finally, Royal Bank of Canada increased their price target on shares of IDEAYA Biosciences from $43.00 to $53.00 and gave the company an "outperform" rating in a research report on Wednesday, February 21st. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $46.80.

IDEAYA Biosciences Trading Up 1.7 %

The company's fifty day simple moving average is $41.89 and its 200 day simple moving average is $39.28. The firm has a market capitalization of $3.10 billion, a P/E ratio of -20.06 and a beta of 0.83.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.02). IDEAYA Biosciences had a negative return on equity of 20.09% and a negative net margin of 483.05%. The company's revenue for the quarter was down 100.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.49) earnings per share. On average, analysts predict that IDEAYA Biosciences, Inc. will post -2.33 earnings per share for the current fiscal year.

Insider Buying and Selling

In other IDEAYA Biosciences news, CEO Yujiro S. Hata sold 56,711 shares of the firm's stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $41.61, for a total transaction of $2,359,744.71. Following the completion of the sale, the chief executive officer now directly owns 677,887 shares in the company, valued at approximately $28,206,878.07. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CEO Yujiro S. Hata sold 34,433 shares of the firm's stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $41.81, for a total value of $1,439,643.73. Following the transaction, the chief executive officer now owns 677,887 shares of the company's stock, valued at $28,342,455.47. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Yujiro S. Hata sold 56,711 shares of the firm's stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $41.61, for a total transaction of $2,359,744.71. Following the completion of the transaction, the chief executive officer now directly owns 677,887 shares in the company, valued at approximately $28,206,878.07. The disclosure for this sale can be found here. 3.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On IDEAYA Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in IDYA. Bank of New York Mellon Corp boosted its holdings in shares of IDEAYA Biosciences by 12.7% in the third quarter. Bank of New York Mellon Corp now owns 196,289 shares of the company's stock worth $5,296,000 after buying an additional 22,121 shares during the last quarter. Teacher Retirement System of Texas lifted its holdings in IDEAYA Biosciences by 6.7% during the third quarter. Teacher Retirement System of Texas now owns 13,741 shares of the company's stock valued at $371,000 after purchasing an additional 867 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in IDEAYA Biosciences by 4.9% during the third quarter. Principal Financial Group Inc. now owns 14,415 shares of the company's stock valued at $389,000 after purchasing an additional 676 shares in the last quarter. Los Angeles Capital Management LLC lifted its holdings in IDEAYA Biosciences by 2.5% during the third quarter. Los Angeles Capital Management LLC now owns 18,802 shares of the company's stock valued at $507,000 after purchasing an additional 456 shares in the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in IDEAYA Biosciences by 6.1% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 9,735 shares of the company's stock valued at $263,000 after purchasing an additional 556 shares in the last quarter. Hedge funds and other institutional investors own 98.29% of the company's stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.